< 0 1 0 1 O
12 2 4 2 4 B-upper_bound
months 5 11 5 11 I-upper_bound
from 12 16 12 16 O
pre 17 20 17 20 O
- 20 21 20 21 O
registration 21 33 21 33 O
on 34 36 34 36 O
this 37 41 37 41 O
study 42 47 42 47 O

Aggressive 0 10 48 58 B-cancer
lymphoma 11 19 59 67 I-cancer

Anaplastic 0 10 68 78 B-cancer
large 11 16 79 84 I-cancer
cell 17 21 85 89 I-cancer
lymphoma 22 30 90 98 I-cancer

Anaplastic 0 10 99 109 B-chronic_disease
large 11 16 110 115 I-chronic_disease
cell 17 21 116 120 I-chronic_disease
lymphoma 22 30 121 129 I-chronic_disease
( 31 32 130 131 I-chronic_disease
T 32 33 131 132 I-chronic_disease
and 34 37 133 136 I-chronic_disease
null 38 42 137 141 I-chronic_disease
cell 43 47 142 146 I-chronic_disease
type 48 52 147 151 I-chronic_disease
) 52 53 151 152 I-chronic_disease

Angioimmunoblastic 0 18 153 171 B-cancer
T 19 20 172 173 I-cancer
- 20 21 173 174 I-cancer
cell 21 25 174 178 I-cancer
lymphoma 26 34 179 187 I-cancer

Before 0 6 188 194 O
diagnosing 7 17 195 205 O
CLL 18 21 206 209 B-cancer
or 22 24 210 212 O
SLL 25 28 213 216 B-cancer
, 28 29 216 217 O
mantle 30 36 218 224 B-cancer
cell 37 41 225 229 I-cancer
lymphoma 42 50 230 238 I-cancer
must 51 55 239 243 O
be 56 58 244 246 O
excluded 59 67 247 255 O
by 68 70 256 258 O
demonstrating 71 84 259 272 O
a 85 86 273 274 O
negative 87 95 275 283 O
fluorescent 96 107 284 295 B-treatment
in 108 110 296 298 I-treatment
situ 111 115 299 303 I-treatment
hybridization 116 129 304 317 I-treatment
( 130 131 318 319 I-treatment
FISH 131 135 319 323 I-treatment
) 135 136 323 324 I-treatment
analysis 137 145 325 333 O
for 146 149 334 337 O
t(11;14)(immunoglobulin 150 173 338 361 O
H 174 175 362 363 O
[ 176 177 364 365 O
IgH]/cyclin 177 188 365 376 O
D 189 190 377 378 O
1 191 192 379 380 O
[ 193 194 381 382 O
CCND1 194 199 382 387 O
] 199 200 387 388 O
) 200 201 388 389 O
on 202 204 390 392 O
peripheral 205 215 393 403 B-treatment
blood 216 221 404 409 I-treatment
or 222 224 410 412 O
tissue 225 231 413 419 B-treatment
biopsy 232 238 420 426 I-treatment
or 239 241 427 429 O
negative 242 250 430 438 O
immunohistochemical 251 270 439 458 O
stains 271 277 459 465 O
for 278 281 466 469 O
cyclin 282 288 470 476 O
D1 289 291 477 479 O
on 292 294 480 482 O
involved 295 303 483 491 O
tissue 304 310 492 498 O
biopsy 311 317 499 505 O

Biopsy 0 6 506 512 B-treatment
- 6 7 512 513 O
proven 7 13 513 519 O
small 14 19 520 525 B-cancer
lymphocytic 20 31 526 537 I-cancer
lymphoma 32 40 538 546 I-cancer

CLL 0 3 547 550 B-cancer
/ 3 4 550 551 O
SLL 4 7 551 554 B-cancer

Capable 0 7 555 562 O
of 8 10 563 565 O
swallowing 11 21 566 576 O
intact 22 28 577 583 O
study 29 34 584 589 B-treatment
medication 35 45 590 600 I-treatment
capsules 46 54 601 609 I-treatment

Diagnosis 0 9 610 619 O
of 10 12 620 622 O
CLL 13 16 623 626 B-cancer

Dim 0 3 627 630 O
surface 4 11 631 638 O
immunoglobulin 12 26 639 653 B-cancer
expression 27 37 654 664 I-cancer

During 0 6 665 671 O
the 7 10 672 675 O
Active 11 17 676 682 O
Monitoring 18 28 683 693 O
Phase 29 34 694 699 O
of 35 37 700 702 O
a 38 39 703 704 O
study 40 45 705 710 O
( 46 47 711 712 O
i.e. 47 51 712 716 O
, 51 52 716 717 O
active 53 59 718 724 O
treatment 60 69 725 734 B-treatment
and 70 73 735 738 O
observation 74 85 739 750 O
) 85 86 750 751 O
, 86 87 751 752 O
participants 88 100 753 765 O
must 101 105 766 770 O
be 106 108 771 773 O
willing 109 116 774 781 O
to 117 119 782 784 O
return 120 126 785 791 O
to 127 129 792 794 O
the 130 133 795 798 O
consenting 134 144 799 809 O
institution 145 156 810 821 O
for 157 160 822 825 O
follow 161 167 826 832 O
- 167 168 832 833 O
up 168 170 833 835 O

Enteropathy 0 11 836 847 B-cancer
- 11 12 847 848 I-cancer
type 12 16 848 852 I-cancer
T 17 18 853 854 I-cancer
- 18 19 854 855 I-cancer
cell 19 23 855 859 I-cancer
lymphoma 24 32 860 868 I-cancer

Extranodal 0 10 869 879 B-cancer
NK 11 13 880 882 I-cancer
/ 13 14 882 883 I-cancer
T 14 15 883 884 I-cancer
- 15 16 884 885 I-cancer
cell 16 20 885 889 I-cancer
lymphoma 21 29 890 898 I-cancer
, 29 30 898 899 O
nasal 31 36 900 905 O
type 37 41 906 910 O

Hepatosplenic 0 13 911 924 B-cancer
T 14 15 925 926 I-cancer
- 15 16 926 927 I-cancer
cell 16 20 927 931 I-cancer
lymphoma 21 29 932 940 I-cancer

Immunophenotyping 0 17 941 958 B-treatment
consistent 18 28 959 969 O
with 29 33 970 974 O
CLL 34 37 975 978 B-cancer

Life 0 4 979 983 B-clinical_variable
expectancy 5 15 984 994 I-clinical_variable
of 16 18 995 997 O
at 19 21 998 1000 O
least 22 27 1001 1006 O
24 28 30 1007 1009 B-lower_bound
months 31 37 1010 1016 I-lower_bound

Newly 0 5 1017 1022 O
diagnosed 6 15 1023 1032 O
de 16 18 1033 1035 O
- 18 19 1035 1036 O
novo 19 23 1036 1040 O
DLBCL 24 29 1041 1046 B-cancer
or 30 32 1047 1049 O
primary 33 40 1050 1057 B-cancer
mediastinal 41 52 1058 1069 I-cancer
B 53 54 1070 1071 I-cancer
- 54 55 1071 1072 I-cancer
cell 55 59 1072 1076 I-cancer
lymphoma 60 68 1077 1085 I-cancer
that 69 73 1086 1090 O
will 74 78 1091 1095 O
be 79 81 1096 1098 O
treated 82 89 1099 1106 O
with 90 94 1107 1111 O
an 95 97 1112 1114 O
anthracycline 98 111 1115 1128 B-treatment
- 111 112 1128 1129 I-treatment
containing 112 122 1129 1139 I-treatment
regimen 123 130 1140 1147 I-treatment
( 131 132 1148 1149 O
rituximab 132 141 1149 1158 B-treatment
- 141 142 1158 1159 O
cyclophosphamide 142 158 1159 1175 B-treatment
, 158 159 1175 1176 O
doxorubicin 160 171 1177 1188 B-treatment
hydrochloride 172 185 1189 1202 I-treatment
, 185 186 1202 1203 O
prednisone 187 197 1204 1214 B-treatment
[ 198 199 1215 1216 I-treatment
R 199 200 1216 1217 I-treatment
- 200 201 1217 1218 I-treatment
CHOP 201 205 1218 1222 I-treatment
] 205 206 1222 1223 I-treatment
or 207 209 1224 1226 O
equivalent 210 220 1227 1237 O
) 220 221 1237 1238 O

Newly 0 5 1239 1244 O
diagnosed 6 15 1245 1254 O
untreated 16 25 1255 1264 O
peripheral 26 36 1265 1275 O
T 37 38 1276 1277 B-cancer
- 38 39 1277 1278 I-cancer
cell 39 43 1278 1282 I-cancer
non 44 47 1283 1286 I-cancer
- 47 48 1286 1287 I-cancer
Hodgkin 48 55 1287 1294 I-cancer
lymphoma 56 64 1295 1303 I-cancer
( 65 66 1304 1305 I-cancer
NHL 66 69 1305 1308 I-cancer
) 69 70 1308 1309 I-cancer
that 71 75 1310 1314 O
will 76 80 1315 1319 O
be 81 83 1320 1322 O
treated 84 91 1323 1330 O
with 92 96 1331 1335 O
chemotherapy 97 109 1336 1348 B-treatment

Peripheral 0 10 1349 1359 B-cancer
T 11 12 1360 1361 I-cancer
cell 13 17 1362 1366 I-cancer
lymphoma 18 26 1367 1375 I-cancer
, 26 27 1375 1376 O
unspecified 28 39 1377 1388 O

Rai 0 3 1389 1392 B-clinical_variable
stage 4 9 1393 1398 I-clinical_variable
0 10 11 1399 1400 B-lower_bound
or 12 14 1401 1403 O
1 15 16 1404 1405 B-upper_bound

Serum 0 5 1406 1411 B-clinical_variable
calcium 6 13 1412 1419 I-clinical_variable
< 14 15 1420 1421 O
11 16 18 1422 1424 B-upper_bound
mg 19 21 1425 1427 I-upper_bound
/ 21 22 1427 1428 I-upper_bound
dL 22 24 1428 1430 I-upper_bound

Subcutaneous 0 12 1431 1443 B-cancer
panniculitis 13 25 1444 1456 I-cancer
- 25 26 1456 1457 I-cancer
like 26 30 1457 1461 I-cancer
T 31 32 1462 1463 I-cancer
- 32 33 1463 1464 I-cancer
cell 33 37 1464 1468 I-cancer
lymphoma 38 46 1469 1477 I-cancer

patient 0 7 1478 1485 O
is 8 10 1486 1488 O
permitted 11 20 1489 1498 O
to 21 23 1499 1501 O
participate 24 35 1502 1513 O
in 36 38 1514 1516 O
any 39 42 1517 1520 O
other 43 48 1521 1526 O
therapeutic 49 60 1527 1538 B-treatment
therapy 61 68 1539 1546 I-treatment
for 69 72 1547 1550 O
their 73 78 1551 1556 O
disease 79 86 1557 1564 O
as 87 89 1565 1567 O
long 90 94 1568 1572 O
as 95 97 1573 1575 O
it 98 100 1576 1578 O
does 101 105 1579 1583 O
not 106 109 1584 1587 O
concern 110 117 1588 1595 O
vitamin 118 125 1596 1603 O
D 126 127 1604 1605 O

patients 0 8 1606 1614 O
can 9 12 1615 1618 O
be 13 15 1619 1621 O
enrolled 16 24 1622 1630 O
up 25 27 1631 1633 O
through 28 35 1634 1641 O
day 36 39 1642 1645 O
1 40 41 1646 1647 O
of 42 44 1648 1650 O
cycle 45 50 1651 1656 O
3 51 52 1657 1658 O
of 53 55 1659 1661 O
therapy 56 63 1662 1669 B-treatment

patients 0 8 1670 1678 O
can 9 12 1679 1682 O
begin 13 18 1683 1688 O
their 19 24 1689 1694 O
chemotherapy 25 37 1695 1707 B-treatment
while 38 43 1708 1713 I-treatment
awaiting 44 52 1714 1722 I-treatment
vitamin 53 60 1723 1730 I-treatment
D 61 62 1731 1732 I-treatment
results 63 70 1733 1740 I-treatment
and 71 74 1741 1744 I-treatment
treatment 75 84 1745 1754 I-treatment
arm 85 88 1755 1758 I-treatment
assignment 89 99 1759 1769 I-treatment

patients 0 8 1770 1778 O
with 9 13 1779 1783 O
B 14 15 1784 1785 B-cancer
cell 16 20 1786 1790 I-cancer
lymphoma 21 29 1791 1799 I-cancer
, 29 30 1799 1800 O
unclassifiable 31 45 1801 1815 O
, 45 46 1815 1816 O
with 47 51 1817 1821 O
features 52 60 1822 1830 O
intermediate 61 73 1831 1843 O
between 74 81 1844 1851 O
diffuse 82 89 1852 1859 B-cancer
large 90 95 1860 1865 I-cancer
B 96 97 1866 1867 I-cancer
cell 98 102 1868 1872 I-cancer
lymphoma 103 111 1873 1881 I-cancer
and 112 115 1882 1885 O
Burkitt 116 123 1886 1893 B-cancer
lymphoma 124 132 1894 1902 I-cancer
or 133 135 1903 1905 O
post 136 140 1906 1910 B-cancer
- 140 141 1910 1911 I-cancer
transplant 141 151 1911 1921 I-cancer
DLBCL 152 157 1922 1927 I-cancer
are 158 161 1928 1931 O
also 162 166 1932 1936 O
eligible 167 175 1937 1945 O

patients 0 8 1946 1954 O
with 9 13 1955 1959 O
composite 14 23 1960 1969 B-cancer
lymphomas 24 33 1970 1979 I-cancer
can 34 37 1980 1983 O
also 38 42 1984 1988 O
be 43 45 1989 1991 O
enrolled 46 54 1992 2000 O
as 55 57 2001 2003 O
long 58 62 2004 2008 O
as 63 65 2009 2011 O
they 66 70 2012 2016 O
have 71 75 2017 2021 O
large 76 81 2022 2027 O
cell 82 86 2028 2032 O
component 87 96 2033 2042 O
and 97 100 2043 2046 O
will 101 105 2047 2051 O
be 106 108 2052 2054 O
treated 109 116 2055 2062 O
with 117 121 2063 2067 O
an 122 124 2068 2070 O
anthracycline 125 138 2071 2084 B-treatment

patients 0 8 2085 2093 O
with 9 13 2094 2098 O
hypercalcemia 14 27 2099 2112 B-chronic_disease
can 28 31 2113 2116 O
be 32 34 2117 2119 O
enrolled 35 43 2120 2128 O
after 44 49 2129 2134 O
the 50 53 2135 2138 O
calcium 54 61 2139 2146 O
is 62 64 2147 2149 O
corrected 65 74 2150 2159 O
with 75 79 2160 2164 O
standard 80 88 2165 2173 O
of 89 91 2174 2176 O
care 92 96 2177 2181 O
treatments 97 107 2182 2192 B-treatment

patients 0 8 2193 2201 O
with 9 13 2202 2206 O
typical 14 21 2207 2214 O
Burkitt 22 29 2215 2222 B-cancer
lymphoma 30 38 2223 2231 I-cancer
are 39 42 2232 2235 O
not 43 46 2236 2239 O
eligible 47 55 2240 2248 O

primary 0 7 2249 2256 B-cancer
cutaneous 8 17 2257 2266 I-cancer
type 18 22 2267 2271 I-cancer

